Evidence map›Paper›PMID 30674353›Full record

ArticleBreast cancer research : BCR2019

Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.

Marie-Julie Nokin, Justine Bellier, Florence Durieux, Olivier Peulen, Gilles Rademaker, Maude Gabriel, Christine Monseur, Benoit Charloteaux, Lieven Verbeke, Steven van Laere and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 101 citations in OpenAlex.

  1. ACS central science · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Dual roles of methylglyoxal in cancer.Frontiers in oncology · 2025
    Review
  13. Review
  14. Protein Haptenation and Its Role in Allergy.Chemical research in toxicology · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 3 countries.

Marie-Julie NokinMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Justine BellierMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Florence DurieuxMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Olivier PeulenMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Gilles RademakerMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Maude GabrielMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Christine MonseurMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Benoit CharloteauxGenomics Platform, GIGA, ULiège, Liège, Belgium.
Lieven VerbekeDepartment of Information Technology, Ghent University, Ghent, Belgium.
Steven van LaereTranslational Cancer Research Unit, University of Antwerp, Antwerp, Belgium.
Patrick RoncaratiLaboratory of Experimental Pathology, GIGA-Cancer, ULiège, Liège, Belgium.
Michael HerfsLaboratory of Experimental Pathology, GIGA-Cancer, ULiège, Liège, Belgium.
Charles LambertLaboratory of Connective Tissues Biology, GIGA-Cancer, ULiège, Liège, Belgium.
Jean ScheijenLaboratory for Metabolism and Vascular Medicine, Department of Internal Medicine, Maastricht University, Maastricht, The Netherlands.
Casper SchalkwijkLaboratory for Metabolism and Vascular Medicine, Department of Internal Medicine, Maastricht University, Maastricht, The Netherlands.
Alain ColigeLaboratory of Connective Tissues Biology, GIGA-Cancer, ULiège, Liège, Belgium.
Jo CaersLaboratory of Hematology, GIGA-Inflammation, Infection and Immunity, ULiège, Liège, Belgium.
Philippe DelvenneLaboratory of Experimental Pathology, GIGA-Cancer, ULiège, Liège, Belgium.
Andrei TurtoiInstitut de Recherche en Cancérologie de Montpellier, Inserm U1194, Montpellier, France.
Vincent CastronovoMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.
Akeila BellahcèneMetastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium. a.bellahcene@uliege.be.ORCID 0000-0001-9154-7631
University of Liège · BEMaastricht University · NLGhent University · BEInserm · FRUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated aerobic glycolysis rate is a biochemical alteration associated with malignant transformation and cancer progression. This metabolic shift unavoidably generates methylglyoxal (MG), a potent inducer of dicarbonyl stress through the formation of advanced glycation end products (AGEs). We have previously shown that the silencing of glyoxalase 1 (GLO1), the main MG detoxifying enzyme, generates endogenous dicarbonyl stress resulting in enhanced growth and metastasis in vivo. However, the molecular mechanisms through which MG stress promotes metastasis development remain to be unveiled.

methodsIn this study, we used RNA sequencing analysis to investigate gene-expression profiling of GLO1-depleted breast cancer cells and we validated the regulated expression of selected genes of interest by RT-qPCR. Using in vitro and in vivo assays, we demonstrated the acquisition of a pro-metastatic phenotype related to dicarbonyl stress in MDA-MB-231, MDA-MB-468 and MCF7 breast cancer cellular models. Hyperactivation of MEK/ERK/SMAD1 pathway was evidenced using western blotting upon endogenous MG stress and exogenous MG treatment conditions. MEK and SMAD1 regulation of MG pro-metastatic signature genes in breast cancer cells was demonstrated by RT-qPCR.

resultsHigh-throughput transcriptome profiling of GLO1-depleted breast cancer cells highlighted a pro-metastatic signature that establishes novel connections between MG dicarbonyl stress, extracellular matrix (ECM) remodeling by neoplastic cells and enhanced cell migration. Mechanistically, we showed that these metastasis-related processes are functionally linked to MEK/ERK/SMAD1 cascade activation in breast cancer cells. We showed that sustained MEK/ERK activation in GLO1-depleted cells notably occurred through the down-regulation of the expression of dual specificity phosphatases in MG-stressed breast cancer cells. The use of carnosine and aminoguanidine, two potent MG scavengers, reversed MG stress effects in in vitro and in vivo experimental settings.

conclusionsThese results uncover for the first time the key role of MG dicarbonyl stress in the induction of ECM remodeling and the activation of migratory signaling pathways, both in favor of enhanced metastatic dissemination of breast cancer cells. Importantly, the efficient inhibition of mitogen-activated protein kinase (MAPK) signaling using MG scavengers further emphasizes the need to investigate their therapeutic potential across different malignancies.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBreast NeoplasmsCell Line, TumorCell MovementDown-RegulationDual-Specificity PhosphatasesFemaleGene Expression ProfilingGene Knockdown TechniquesGlycolysisHumansLactoylglutathione LyaseMAP Kinase Signaling SystemMicePyruvaldehydeDual-Specificity PhosphatasesDUSP5 protein, humanGLO1 protein, humanLactoylglutathione LyasePyruvaldehydeRNA, Small InterferingSmad1 ProteinSMAD1 protein, humanBreast cancerCarnosineMAPKMetastasisMethylglyoxalSMAD1

Identifiers

PMID30674353
PMCPMC6343302
OpenAlexW2921750600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.